GERN Earnings Date: Nov 4, 2026 (Estimated) — Geron Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is GERN's next earnings date?
Geron Corporation (GERN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.01 on revenue of $60.4M.
How did GERN do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Geron Corporation posted EPS of -$0.02 versus the -$0.01 estimate, a miss of 100.0%. Revenue was $57.5M against a $55.3M estimate. The stock's 1-day post-earnings move was +21.6%.
How much does GERN stock move after earnings?
GERN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.5% (up or down) in the day after earnings.
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.01 | -0.02 | -100.00% | $57.5M | ❌ Miss | +21.64% | +21.64% | +18.66% |
| 2026-05-06 | Q1 2026 | -0.02 | -0.01 | +50.00% | $51.8M | ✅ Beat | -4.24% | -15.15% | -26.67% |
| 2026-02-25 | Q4 2025 | -0.04 | -0.05 | -25.00% | $48.0M | ❌ Miss | -11.79% | -26.15% | -19.49% |
| 2025-11-05 | Q3 2025 | -0.04 | -0.03 | +25.00% | $47.2M | ✅ Beat | -5.22% | +8.70% | +10.43% |
| 2025-08-06 | Q2 2025 | -0.03 | -0.02 | +33.33% | $49.0M | ✅ Beat | +15.83% | +12.50% | +15.00% |
| 2025-02-26 | Q4 2024 | -0.05 | -0.04 | +20.00% | $47.5M | ✅ Beat | -32.07% | -29.96% | -28.27% |
| 2024-11-07 | Q3 2024 | -0.08 | -0.04 | +50.00% | $28.3M | ✅ Beat | +0.47% | -9.37% | -7.96% |
| 2024-08-08 | Q2 2024 | -0.10 | -0.10 | +0.00% | $882,000 | ➖ Inline | +0.88% | -2.63% | -6.80% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $129.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Revenues Before Adjustments | 55.8% | $72.4M | +25.2% | $56.8M | $45.3M | $57.9M | $60.2M |
| Product | 44.2% | $57.5M | +17.3% | $48.3M | $39.4M | $49.0M | $47.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.